HR 5882
116th Congress
House
Health
Administrative law and regulatory procedures
Appropriations
Congressional oversight
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Drug therapy
Genetics
Government studies and investigations
Health care costs and insurance
Home and outpatient care
Intergovernmental relations
Manufacturing
Medicaid
Prescription drugs
State and local government operations
GENE Therapy Payment Act
Introduced: February 12, 2020
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 12, 2020
Referred to the House Committee on Energy and Commerce.
Feb 12, 2020
Introduced in House
Plain-English summary
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act
This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
What's happening now
Referred to the House Committee on Energy and Commerce.
Committees of jurisdiction
1